<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhou X</submitter><funding>the Beijing Municipal Science &amp;amp; Technology commission national key research and development plan matching project</funding><pagination>599-605</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8018348</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>43(1)</volume><pubmed_abstract>The serum intact parathyroid hormone (iPTH) is associated with the prognosis of hemodialysis (HD) patients, however, its optimal range for reducing mortality remains inconsistent. We designed a prospective cohort study of 346 incident HD patients to assess the association between different serum iPTH level and mortality. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI) international guidelines (2003), we divided patients into three groups (iPTH &lt; 150 pg/mL, 150-300 pg/mL and >300 pg/mL). During the median follow-up of 58 months, 157 patients (45.38%) died. Multivariate Cox regression analysis showed that iPTH &lt; 150 pg/mL and >300 pg/mL were associated with all-cause and cardiovascular mortality. Then, we performed a sensitivity analysis of patients divided into 6 serum </pubmed_abstract><journal>Renal failure</journal><pubmed_title>The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients.</pubmed_title><pmcid>PMC8018348</pmcid><funding_grant_id>Z161100002616005</funding_grant_id><pubmed_authors>Guo Y</pubmed_authors><pubmed_authors>Luo Y</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors></additional><is_claimable>false</is_claimable><name>The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients.</name><description>The serum intact parathyroid hormone (iPTH) is associated with the prognosis of hemodialysis (HD) patients, however, its optimal range for reducing mortality remains inconsistent. We designed a prospective cohort study of 346 incident HD patients to assess the association between different serum iPTH level and mortality. According to the Kidney Disease Outcomes Quality Initiative (K/DOQI) international guidelines (2003), we divided patients into three groups (iPTH &lt; 150 pg/mL, 150-300 pg/mL and >300 pg/mL). During the median follow-up of 58 months, 157 patients (45.38%) died. Multivariate Cox regression analysis showed that iPTH &lt; 150 pg/mL and >300 pg/mL were associated with all-cause and cardiovascular mortality. Then, we performed a sensitivity analysis of patients divided into 6 serum </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2025-04-04T12:34:07.686Z</modification><creation>2025-04-04T12:34:07.686Z</creation></dates><accession>S-EPMC8018348</accession><cross_references><pubmed>33781171</pubmed><doi>10.1080/0886022X.2021.1903927</doi></cross_references></HashMap>